חוב כולל להון RenovoRx Corp (RNXT)

RenovoRx, Inc. (RNXT) efficiency relies on the precise transportation of complex catheters and medications to hospitals. The company is implementing targeted chemotherapy methods in clinics, creating long-term demand for high-margin consumables. Production capacities and contract sites are fully prepared for volume growth without interruptions. The asset value tracked on the chart, characterizing the total debt-to-equity ratio, stands at 0.04.

For RenovoRx, Inc. (RNXT), which depends on clinical trial outcomes and R&D burn rates, maintaining control over financial stability is critical. This ratio, calculated as total liabilities to equity, determines the business's degree of dependence on borrowed capital and the associated bankruptcy risks. By analyzing the shifting proportion of total debt to equity, an investor assesses the balance between the credit load and the company's financial autonomy.